Merck & Co. shaved the top end of its 2025 revenue guidance and failed to produce any standout sales beats for its medicines ...

With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...

Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid ...

Merck & Co beat third-quarter (3Q) sales expectations on strong results from its pneumonia vaccine as the company works to ...

Pharmaceutical giant Merck & Co. is breaking ground on a $3 billion expansion of its longtime Elkton manufacturing campus, a ...

Q3 earnings beat estimates, but shares dip as 2025 sales outlook narrows. Get key highlights and pharma market insights.

Discover Merck & Co., Inc.'s Q3 earnings outlook as Keytruda's patent nears expiry. Click for my updated look at MRK stock ...

While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.

The company will begin its domestic investment by starting construction on a $3 billion pharmaceutical manufacturing site in ...

Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life ...